EP2136873A1 - Dispositif non chirurgical et procédés de stimulation du nerf vague trans- sophagien - Google Patents

Dispositif non chirurgical et procédés de stimulation du nerf vague trans- sophagien

Info

Publication number
EP2136873A1
EP2136873A1 EP08727307A EP08727307A EP2136873A1 EP 2136873 A1 EP2136873 A1 EP 2136873A1 EP 08727307 A EP08727307 A EP 08727307A EP 08727307 A EP08727307 A EP 08727307A EP 2136873 A1 EP2136873 A1 EP 2136873A1
Authority
EP
European Patent Office
Prior art keywords
support member
esophagus
medical device
imd
implantable medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08727307A
Other languages
German (de)
English (en)
Inventor
Timothy L. Scott
Steven E. Maschino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Livanova USA Inc
Original Assignee
Cyberonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/796,158 external-priority patent/US7869884B2/en
Priority claimed from US11/796,058 external-priority patent/US7904175B2/en
Application filed by Cyberonics Inc filed Critical Cyberonics Inc
Publication of EP2136873A1 publication Critical patent/EP2136873A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0517—Esophageal electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114—Cardiac control, e.g. by vagal stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551—Spinal or peripheral nerve electrodes

Definitions

  • the subject matter of this disclosure generally relates to the field of medical devices. More specifically, the present disclosure relates to non-surgically implantable medical devices and methods for implementing vagus nerve therapy.
  • Such devices include pacemakers and defibrillators, which provide electrical signal therapy to heart tissue, as well as spinal cord stimulators for treatment of pain.
  • devices have also been approved to provide electrical signal therapy to the vagus nerve (the 10 th cranial nerve) to treat epilepsy and depression.
  • Additional medical devices for providing electrical signal therapy have been proposed for stimulation of other nerves, such as the sympathetic nerve, the phrenic nerve and the occipital nerve.
  • signal therapy have been proposed for stimulation of other nerves, such as the sympathetic nerve, the phrenic nerve and the occipital nerve.
  • the vagus nerve (cranial nerve X) is the longest nerve in the human body. It originates in the brainstem and extends, through the jugular foramen, down below the head, to the abdomen. Branches of the vagus nerve innervate various organs of the body, including the heart, the stomach, the lungs, the kidneys, the pancreas, and the liver.
  • a medical device such as an electrical signal generator has been coupled to a patient's vagus nerve to treat a number of medical conditions.
  • electrical signal therapy for the vagus nerve often referred to as vagus nerve stimulation (VNS) has been approved in the United States and elsewhere to treat epilepsy and depression.
  • VNS vagus nerve stimulation
  • vagus nerve Application of an electrical signal to the vagus nerve is thought to affect some of its connections to areas in the brain that are prone to seizure activity. Because of the vagus nerve's innervation of the stomach, stimulating the vagus nerve may also be therapeutically beneficial to treating eating disorders such as bulimia nervosa, as well as treating morbid obesity.
  • VNS treatments have involved surgically coupling electrodes to the left and/or right vagus nerves in the neck.
  • Other treatments involve surgically implanting electrodes to one or more surfaces in the abdomen, such as by laparoscopic surgery through the patient's abdominal wall.
  • Electrical signal therapies in addition to VNS have been proposed to treat eating disorders such as obesity. These techniques include coupling electrodes to the exterior and/or interior of the stomach, duodenum, or intestinal walls.
  • all of the aforementioned therapies either do not provide stimulation directed specifically to the vagus nerve, substantially interfere with normal gastrointestinal function, require some type of invasive surgery, or all of the above.
  • the present invention provides devices and methods for non-surgically providing vagus nerve therapy to treat a variety of medical conditions.
  • Embodiments of an IMD provide electrical stimulation to the vagus nerve through the wall of the esophagus (i.e. trans-esophageally) via a device coupled to the inner surface of the esophagus.
  • implantation of the IMD may be accomplished non-surgically by oral insertion, precluding the need for incisions or even laparoscopic surgery.
  • an implantable medical device for providing a therapeutic electrical signal to a vagus nerve of a patient comprises a support member having an outer surface.
  • the support member is adapted to engage the inner wall of an esophagus.
  • the IMD also comprises at least one electrode disposed on the outer surface of the support member.
  • the at least one electrode is adapted to apply a trans-esophageal electrical signal to a vagus nerve through the wall of the esophagus from the inner lumen thereof.
  • the implantable medical device further comprises a signal generator coupled to the support member and to the at least one electrode. The signal generator generates the electrical signal for application to the vagus nerve to treat a medical condition.
  • an implantable medical device comprises a support member having an outer surface adapted to engage an inner surface of an esophagus of a patient.
  • the implantable medical device comprises at least one electrode coupled to the outer surface of the support member.
  • the at least one electrode is adapted to apply an electrical signal to a vagus nerve through the wall of the esophagus.
  • the implantable medical device comprises a signal generator coupled to the support member and to the at least one electrode.
  • the signal generator is capable of generating an electrical signal for application to a vagus nerve of the patient.
  • the implantable medical device comprises a power supply coupled to said support member and to the signal generator.
  • the power supply is capable of providing electrical power to the signal generator.
  • a medical device system comprises a support member having an outer surface. The outer surface is adapted to engage an inner surface of an esophagus of a patient.
  • the system also comprises at least one electrode coupled to the outer surface of the support member and adapted to apply a therapeutic electrical signal trans-esophageally to a vagus nerve of the patient.
  • the system comprises a signal generator coupled to the support member and to the at least one electrode. The signal generator is capable of generating said electrical signal for application to a vagus nerve.
  • the system comprises a power supply for providing electrical power to said signal generator.
  • the system also comprises an external programming system for programming one or more parameters defining said therapeutic electrical signal.
  • a method of providing electrical signal therapy to a vagus nerve of a patient comprises implanting a medical device which includes at least one electrode in the lumen of the abdominal portion of the esophagus of the patient such that the at least one electrode is in contact with the surface of the esophagus wall.
  • the method further comprises applying an electrical signal to at least one vagus nerve of the patient through the wall of the esophagus to treat a medical condition of the patient.
  • a method of providing electrical signal therapy to a vagus nerve of a patient comprises using an ambulatory medical device to apply an electrical signal trans- esophageally to a vagus nerve of the patient from inside the abdominal portion of an esophagus.
  • a method of providing an electrical signal therapy to a vagus nerve of a patient comprises providing an ambulatory medical device, which in turn comprises a support member having an outer surface, at least one electrode on the outer surface of the support member, and an electrical signal generator coupled to the support member and to the at least one electrode.
  • the method further comprises non-surgically implanting the ambulatory medical device, generating a therapeutic electrical signal using the electrical signal generator, and applying the therapeutic electrical signal trans-esophageally to a vagus nerve of a patient from inside the abdominal portion of the patient's esophagus.
  • FIGURE 1 depicts, in schematic form, an embodiment of an implantable medical device
  • IMD IMD
  • IMD implanted within a patient and an external' device for programming the IMD and, in an alternative embodiment, providing power to the IMD;
  • FIGURE 2 illustrates an enlarged view of an embodiment of the IMD implanted inside the abdominal portion of the esophagus
  • FIGURES 3 A-D illustrate embodiments of an IMD according to the present invention
  • FIGURE 4 is a block diagram of an IMD for use in an embodiment of the present invention, and an external unit for communication and programming of the IMD;
  • FIGURES 5A-B illustrate embodiments of implantable medical devices according to the present invention
  • FIGURE 6 illustrates an embodiment of an IMD according to the present invention
  • FIGURE 7 is a schematic view of an IMD and a programming system that may be used in conjunction with embodiments of the IMD; and implantable medical device according to the present invention
  • FIGURE 7 is a block diagram illustrating an external programming system and wand for communication and programming of implantable medical devices according to the present invention.
  • FIGURES 8A-D illustrate an embodiment of a method of non-surgically implanting an
  • IMD for providing trans-esophageal VNS to a patient to treat a medical condition.
  • implantable medical device refers to any medical device placed inside the human body.
  • the placement of such a device may occur in a body lumen of the patient, such as the esophagus or a blood vessel, or may involve surgical implantation, such as when a conventional VNS system is implanted in the patient's chest and neck area.
  • non-surgical is used to describe methods that do not require incision or dissection of body tissues to effect implantation of an IMD.
  • non-surgical implantation may involve placing a medical device in the esophagus of a patient using, e.g., laparoscopic instruments extending from the patient's mouth, through the throat, and into the esophagus.
  • a “therapeutic signal” refers to a stimulation signal delivered to a patient's body with the intent of treating a medical condition by providing a modulating effect to neural tissue.
  • Stimulate or “stimulation signal” refers to the application of an electrical, mechanical, magnetic, electro-magnetic, photonic, audio and/or chemical signal to a neural structure in the patient's body.
  • the signal is an exogenous signal that is distinct from the endogenous, electrical, mechanical, and chemical activity (e.g., afferent and/or efferent electrical action potentials) generated by the patient's body and environment.
  • the stimulation signal (whether electrical, mechanical, magnetic, electro-magnetic, photonic, audio or chemical in nature) applied to the nerve in the present invention is a signal applied from an artificial source, e.g., a neurostimulator.
  • an artificial source e.g., a neurostimulator.
  • the effect of a stimulation signal on neural activity is termed “modulation”; however, for simplicity, the terms “stimulating” and “modulating”, and variants thereof, may be used interchangeably.
  • the application of an exogenous signal to a nerve refers to "stimulation" of the neural structure, while the effects of that signal, if any, on the electrical activity of the neural structure are properly referred to as "modulation.”
  • the term "ambulatory” may describe implantable medical devices, portions of which a patient may carry around with minimal effect or interruption to his or her daily lifestyle.
  • electrical neurostimulation may be provided by implanting an electrical device (e.g., a pulse generator) underneath the skin of a patient and delivering an electrical signal to a nerve such as a cranial nerve.
  • the electrical neurostimulation involves sensing or detecting a body parameter, with the electrical signal being delivered in response to the sensed body parameter. This type of stimulation is generally referred to as “active,” “feedback,” or “triggered” stimulation.
  • the system may operate without sensing or detecting a body parameter once the patient has been diagnosed with a medical condition that may be treated by neurostimulation.
  • the system may apply a series of electrical pulses to the nerve (e.g., a cranial nerve such as a vagus nerve) periodically, intermittently, or continuously throughout the day, or over another predetermined time interval.
  • This type of stimulation is generally referred to as “passive,” “non-feedback,” or “prophylactic,” stimulation.
  • the electrical signal may be applied by an IMD that is implanted within the patient's body. In other cases, the signal may be generated by an external pulse generator outside the patient's body, coupled by an RF or wireless link to an implanted electrode.
  • neurostimulation signals that perform neuromodulation are delivered by the IMD via one or more leads.
  • the leads generally terminate at their distal ends in one or more electrodes, and the electrodes, in turn, are electrically coupled to tissue in the patient's body.
  • the electrodes are electrically coupled to tissue in the patient's body.
  • a number of electrodes may be attached to various points of a nerve or other tissue inside a human body for delivery of a neurostimulation signal.
  • electrodes are coupled to the electrical signal generator without the use of leads.
  • some embodiments include leads and some embodiments do not incorporate leads.
  • VNS vagus nerve stimulation
  • conventional vagus nerve stimulation usually involves non-feedback stimulation characterized by a number of parameters.
  • convention vagus nerve stimulation usually involves a series of electrical pulses in bursts defined by an "on-time” and an "off -time.”
  • electrical pulses of a defined electrical current e.g., 0.5 - 2.0 milliamps
  • pulse width e.g., 0.25 - 1.0 milliseconds
  • a defined frequency e.g., 20 - 30 Hz
  • the pulse bursts are separated from one another by the off-time, (e.g., 30 seconds - 5 minutes) in which no electrical signal is applied to the nerve.
  • the on-time and off -time parameters together define a duty cycle, which is the ratio of the on-time to the combination of the on-time and off-time, and which describes the percentage of time that the electrical signal is applied to the nerve.
  • the on-time and off-time may be programmed to define an intermittent pattern in which a repeating series of electrical pulse bursts are generated and applied to the vagus nerve.
  • Each sequence of pulses during an on-time may be referred to as a "pulse burst.”
  • the burst is followed by the off-time period in which no signals are applied to the nerve.
  • the off-time is provided to allow the nerve to recover from the stimulation of the pulse burst, and to conserve power. If the off -time is set at zero, the electrical signal in conventional VNS may provide continuous stimulation to the vagus nerve.
  • the idle time may be as long as one day or more, in which case the pulse bursts are provided only once per day or at even longer intervals.
  • the ratio of "off-time" to "on-time” may range from about 0.5 to about 10.
  • the other parameters defining the electrical signal in conventional VNS may be programmed over a range of values.
  • the pulse width for the pulses in a pulse burst of conventional VNS may be set to a value not greater than about 1 msec, such as about 250-500 ⁇ sec, and the number of pulses in a pulse burst is typically set by programming a frequency in a range of about 20-150 Hz (i.e., 20 pulses per second to 150 pulses per second).
  • a non-uniform frequency may also be used. Frequency may be altered during a pulse burst by either a frequency sweep from a low frequency to a high frequency, or vice versa.
  • the timing between adjacent individual signals within a burst may be randomly changed such that two adjacent signals may be generated at any frequency within a range of frequencies.
  • an implantable medical device may be implanted within a patient's body without surgery.
  • the IMD generates and applies an electrical signal to the vagus nerve of the patient to treat a medical condition.
  • the invention is possible because of the unique anatomy of the left and right vagus nerves.
  • the left vagus nerve rotates anteriorly and becomes attached to the exterior surface of the abdominal or lower esophagus (Le. the abdominal portion of the esophagus) as the anterior vagus nerve.
  • abdominal esophagus and “lower esophagus” may be used interchangeably to refer to the portion of the esophagus running from the thorax to the esophagogastric junction of a patient.
  • the right vagus nerve rotates posteriorly and becomes attached to the exterior surface of the lower esophagus as the posterior vagus nerve.
  • the nerves As the anterior and posterior vagus nerves travel down the esophagus, the nerves separate into a number of branches at the esophagus/stomach junction, and the branches remain attached to the outer wall of the stomach.
  • the close proximity of the nerves to the surfaces of the abdominal esophagus and the stomach permit the application of an electrical signal to the vagus nerve from the interior of the abdominal esophagus using a medical device coupled to the esophagus's interior wall.
  • the invention may include devices and methods for providing electrical signal therapy across the wall of the upper portion of the stomach rather than the abdominal portion of the esophagus.
  • the greater accessibility of the vagus nerves at the lower esophagus/stomach junction makes delivery of the signal across the wall of the lower esophagus a preferred embodiment.
  • Application of a therapeutic electrical signal to the stomach is more difficult than the esophagus for a number of reasons.
  • the motility of the esophagus is less than that of the stomach, thus making the esophagus a more stable structure.
  • the anterior and posterior vagus nerves are essentially a unitary structure (i.e., a single nerve bundle — albeit with thousands of individual nerve fibers within it — traveling down the length of the lower esophagus), with limited branching until passing onto the surface of the stomach. Accordingly, stimulation of the vagus at the lower esophagus level facilitates modulation of a larger population of nerves than stimulation of only some of the vagus nerve branches on the upper portion of the stomach.
  • an ambulatory implantable medical device may be non-surgically implanted within the abdominal esophagus of a patient to deliver an electrical signal to at least one of the anterior or posterior vagus nerves through the wall of the esophagus.
  • FIGURES 1 and 2 depict an IMD 100 implanted in a patient.
  • IMD 100 comprises a support member 101.
  • Support member 101 comprises a flexible, biocompatible material and is adapted to be coupled to the inner wall of the lower esophagus of the patient.
  • support member 101 has one or more electrodes 103 coupled to its outer surface.
  • An electrical signal generator 122 generates a therapeutic electrical signal to apply to the vagus nerve 133.
  • Signal generator 122 is electrically coupled to electrodes 103.
  • the electrodes 103 are coupled to the electrical signal generator 122 by leads, while in alternative embodiments the electrodes are directly connected to the electrical signal generator without the use of leads.
  • programming system 120 may be coupled to electrical signal generator 122. Programming system 120 may generally control and monitor IMD 100 from outside the body as IMD 100 provides stimulation to the vagus nerve to provide therapy to a patient.
  • the support member 101 has at least one unipolar electrode coupled to its outer surface. In another embodiment, the support member 101 has a plurality of unipolar electrodes on its outer surface.
  • the plurality of electrodes may include a first plurality on a first side of the support member 101, and a second plurality on a second side of the support member 101.
  • the first plurality may be adapted to provide a trans-esophageal therapeutic electrical signal to an anterior vagus nerve of the patient
  • the second plurality of electrodes may be adapted to provide a trans-esophageal therapeutic electrical signal (which may be the same as or different from the signal provided by the first plurality) to a posterior vagus nerve of the patient.
  • Electrodes 103 are used to apply an electrical signal to the vagus nerve 133 through the wall of the lower esophagus 131. In one embodiment, the electrodes 103 contact or engage the inner wall of the esophagus 131.
  • the electrodes are adapted to partially penetrate the wall of the lower esophagus 131. In a still further embodiment, the electrodes are adapted to completely penetrate the wall of the lower esophagus 131, and in yet another embodiment, the electrodes may comprise multiple electrode elements, some of which contact the inner wall of the esophagus, some of which partially penetrate the esophagus wall, and some of which completely penetrate the wall.
  • support member 101 has at least one electrode pair (e.g., a cathode and an anode) coupled to its outer surface. In another embodiment, support member 101 has a plurality of electrode pairs on its outer surface. In a further embodiment, support member 101 has at least one unipolar electrode as well as at least one electrode pair on its outer surface. In general, the disposition of electrodes (whether unipolar, bipolar, or a combination of unipolar and bipolar electrodes) may be used to steer the electrical current of the therapeutic electrical signal to effectively modulate the anterior and/or posterior vagus nerves of the patient. [0043] IMD 100 is preferably implanted non-surgically, as described below in more detail.
  • IMD 100 is implanted in the lower or abdominal portion of the esophagus via oral insertion of the IMD 100 through the patient's mouth and passage through the throat and the upper esophagus. Since IMD 100 is implanted within the lower esophagus, no incisions are necessary to position the IMD 100 at the desired implantation site.
  • the IMD 100 may be retained in place and migration prevented by suitable anchors to engage the tissue of the esophagus 131.
  • the anchors may comprise any of a number of medical anchors known in the art, e.g., sutures, barbs, staples, adhesives, pins, etc.
  • the IMD 100 may further comprise a retainment element to facilitate maintaining the device in position in the esophagus and to prevent migration.
  • the support member 101 comprises a ring or partial ring structure with a retainment element comprising a resilient spring made of metal or other suitable material.
  • the resilient spring may be embedded in or coupled to support member 101 (e.g., by mechanical affixation).
  • Support member 101 ring or partial ring may be sized to be slightly larger than the diameter of the patient's esophagus, such that the resilient spring retainment element coupled thereto provides a radially outwardly directed force against the lower esophagus to maintain the device in a fixed position in the esophagus, while allowing the IMD 100 to flex with normal movement of the esophagus.
  • IMD 100 provides therapy to the patient by generating and applying an electrical signal to the vagus nerve across the wall of the esophagus 131.
  • trans-esophageal or trans-esophageally” refer to or describe delivery of a therapy (i.e.
  • the signal preferably comprises an electronic signal generated by the electronic signal generator 122 in the inner lumen of the esophagus and applied trans-esophageally to the vagus nerve on the outer surface of the esophagus wall.
  • the electrical signal provided by the electronic signal generator 122 may be defined by programming system 120.
  • the patient may control and/or alter the therapy by a user signal, e.g., a magnet, a tap sensor, or a patient module for noninvasively transmitting and/or receiving data from the IMD 100, e.g., by RF signals.
  • neurostimulation signals that perform neuromodulation are delivered by the IMD 100 via one or more electrodes 103 as shown in Figure 2.
  • the modulating effect of the neurostimulation signal upon the neural tissue may be excitatory or inhibitory, and may potentiate acute and/or long-term changes in neuronal activity.
  • the "modulating" effect of the stimulation signal to the neural tissue may comprise one more of the following effects: (a) initiation of an action potential (afferent and/or efferent action potentials); (b) inhibition or blocking of the conduction of action potentials, whether endogenous or exogenously induced, including hyperpolarizing and/or collision blocking, (c) affecting changes in neurotransmitter/neuromodulator release or uptake, and (d) changes in neuro-plasticity or neurogenesis of brain tissue.
  • the support member 101 is a ring-shaped or tube-shaped member defining a circular cross-section as shown in Figure 3.
  • the diameter of the support member 101 may be sized to match or slightly exceed the diameter of the esophagus 131.
  • support member 101 may be semi-circular, Le., comprising an incomplete circle or a C-shape as shown in Figure 5B.
  • support member 102 may be of any suitable geometry that conforms to at least a portion of the inner surface of an organ.
  • the support member 101 comprises a generally planar, flexible member that is capable of bending to conform to a portion of the inner wall of the lower esophagus 131.
  • support member 101 may be comprised of a biocompatible polymer such as silicone rubber in a suitable shape, i.e., a circular shape, a rectangular shape, or any desired shape, and may have an electrical signal generator 122 coupled thereto (for example by embedding the electrical signal generator in the biocompatible polymer). Furthermore, in such an embodiment, support member 101 may be attached to inner wall of esophagus by using a tissue adhesive or biocompatible glue.
  • a biocompatible polymer such as silicone rubber in a suitable shape, i.e., a circular shape, a rectangular shape, or any desired shape
  • support member 101 may be attached to inner wall of esophagus by using a tissue adhesive or biocompatible glue.
  • the support member 101 has a contracted position to facilitate introduction and implantation of the device in the esophagus, and an expanded position engaging the inner wall of the esophagus to maintain the device in position and reduce or eliminate migration.
  • the support member 101 has a fixed expanded position to hold the device in place within the esophagus.
  • support member 101 may comprise a retainment element that may be a resilient spring member or a stent to provide a radially outwardly directed force against the inner wall of the esophagus.
  • support member 101 and the retainment element may be mounted on a catheter in the first, contracted position to facilitate introduction of the IMD 100 into the patient's mouth and passage through the upper esophagus into the lower esophagus, whereupon the IMD 100 may be deployed in the expanded position and optionally further retained in position with one or more anchor members.
  • support member 101 may further comprise one or more anchor members (not shown) for attaching the IMD 100 to the inner wall of the esophagus 131.
  • support member 101 may comprise a plurality of suture elements such as a suture ring or apertures so that a surgeon may suture the IMD 100 to the inner esophageal wall to prevent displacement of the IMD 100.
  • the anchor members may comprise a plurality of barbs or protrusions which are capable of grasping or engaging the inner surface of the esophagus, and/or of penetrating the wall of the esophagus, to prevent movement or displacement.
  • the barbs or protrusions may be disposed in close proximity to the electrodes 103 so as to stabilize the IMD 100 in a fixed position relative to the anterior and/or posterior vagus nerves.
  • the electrodes 103 may serve as anchor members.
  • electrodes 103 themselves may comprise protrusions which project radially from the support member 101 to engage the wall of the esophagus 131.
  • the electrodes 103 may contact the inner surface of the esophagus wall, and/or may comprise barbs to penetrate the wall in whole or part.
  • Another means of engaging the inner wall of the esophagus comprises a tissue adhesive or biocompatible glue coated on to the outer surface of support member 101.
  • the support member 101 may be made of any suitable biocompatible material.
  • the materials used in fabricating the IMD 100 are preferably non- toxic such that if the IMD 100 is dislodged into the stomach, it may easily pass through the digestive system.
  • support member 101 is made of a resilient or flexible biocompatible material such as a polymer. Suitable polymers include without limitation, hydrogels, silicone, polyethylene, polypropylene, polyurethane, polycaprolactone, polytetrafluoroethylene (PTFE), copolymers and combinations of the foregoing, and the like.
  • the support member is made of a silicone polymer.
  • support member 101 is made of biocompatible metals such as without limitation, titanium, silver, gold, alloys, nitinol, shape-memory metals, or combinations thereof.
  • support member 101 may be made of biological materials such as tissue-engineered esophageal tissue from an animal donor, bovine pericardium, and the like. Where human or animal tissue from a donor is used, the materials are preferably decellularized and cross-linked to minimize adverse immunological reactions and prevent the immune system of the patient from degrading the materials.
  • FIG. 6 illustrates an embodiment of an IMD 100.
  • IMD 100 may comprise a retainment element 142 comprising a skeleton or frame embedded within a support member 101.
  • the support member may in some embodiments comprise a polymer exterior or coating 144 (e.g., a fabric exterior or engineered polymer to provide improved biocompatibility).
  • the retainment element 142 (depicted in a grid-like configuration although many other geometries may be employed) may be made of a flexible metal or polymer, and has sufficient stiffness when support member 101 is in an expanded position to maintain the position of the IMD 100 in the esophagus.
  • the support member 101 serves as a substrate to which to mount the electrodes 103 and other components of the IMD 100 (e.g., a pulse generator and a controller).
  • the exterior/coating 144 comprises a fatty acid derivative covalently bonded to a silicone polymer comprising the support member 101.
  • the support member 101 and the retainment element 142 when expanded, they typically have a diameter or size that corresponds to the inner dimensions of the esophagus.
  • the esophagus has an inner diameter ranging from approximately 10 mm to approximately 30 mm.
  • the support member 101 has an expanded size ranging from approximately 8 mm to about 50 mm, preferably from about 10 mm to about 40 mm, more preferably from about 10 mm to about 35 mm in diameter.
  • different support members 101 may be fabricated with different sizes such that a surgeon may have the option of selecting the most appropriate size depending on the patient.
  • the exterior or outer surface of the support member 101 comprises one or more electrodes 103 which apply a therapeutic electrical signal to the wall of the lower esophagus 131.
  • the electrodes 103 may provide an electrical signal therapy across the wall of the upper portion of the stomach instead of or in addition to the lower portion of the esophagus.
  • electrodes 103 are disposed on support member 101 such that they will be in close proximity to the vagus nerve when the IMD 100 is non-surgically implanted in the esophagus.
  • the electrodes comprise a conductive material such as platinum, iridium, platinum-iridium alloys, gold, silver, copper, aluminum, and/or oxides of the foregoing.
  • the electrodes 103 may be arranged in any suitable pattern on the exterior of the ring.
  • the pattern is preferably optimized to deliver electrical stimulation to the anterior and/or posterior vagus nerves regardless of the location of the IMD 100 within the esophagus.
  • electrodes 103 are arranged as parallel bands or rings around all or part of the outer surface of the IMD 100 as shown in Figure 3 A.
  • electrodes 103 are arranged as rows of circular or hemispherical contacts as shown in Figures 3B and 3D, respectively.
  • electrodes 103 are arranged in vertical columns of electrodes, with each column acting as a unipolar electrode, a cathode or an anode (Figure 3C).
  • Figure 3D also depicts other components of the IMD 100 embedded in support member 101, including a power supply 430, a signal generation unit 420, and a controller 410, as more fully discussed with regard to Figure 4, below.
  • apertures 104 may be provided as shown in Figure 3D for use in conjuction with an anchor member (not shown) such as a suture, barb, pin, etc. This may facilitate modulation of the vagus nerve if rows of electrodes are placed on either side of the descending vagus nerve bundle(s).
  • FIG. 4 illustrates a block diagram depiction of the IMD 400 of Figure 1, in accordance with one illustrative embodiment of the present invention.
  • the IMD 400 may be used for electrical signal therapy to treat various disorders, such as (without limitation) epilepsy, depression, bulimia, heart rhythm disorders, gastric-related disorder, a hormonal disorder, a reproductive disorder, a metabolic disorder, a hearing disorder, and/or a pain disorder.
  • the IMD 400 may be coupled to various leads, if necessary, and one or more electrodes for applying a therapeutic electrical signal to an anterior and/or posterior vagus nerve of the patient.
  • Therapeutic electrical signals may be transmitted from the IMD 400 to a lower esophagus wall of the patient, and across the wall of the esophagus to the patient.
  • the electrodes may be positioned either in contact with the inner wall of the esophagus, or may penetrate the wall of the esophagus in whole or in part.
  • the net effect of the IMD 400 and the electrodes is to generate an electrical signal in the inner lumen of the esophagus and to transmit that signal from the inner lumen to a vagus nerve located outside the wall of the esophagus.
  • Therapeutic electrical signals from the IMD 400 may be generated by a signal generation unit 420 and transmitted to the electrode(s) either directly or via one or more leads (not shown).
  • signals from sensor electrodes may also be coupled to the IMD 400.
  • the electrodes applying the signal to the vagus nerve may also function as sensing electrodes.
  • Sensing electrodes may be used to trigger feedback stimulation routines based upon, e.g., body temperature, EEG recordings, heart rate, vagus nerve activity, etc.
  • the IMD 400 may comprise a controller 410 capable of controlling various aspects of the operation of the IMD 400.
  • the controller 410 is capable of receiving internal data and/or external data and controlling the generation and delivery of a therapeutic electrical signal to a vagus nerve of the patient's body.
  • the controller 410 may receive manual instructions from an operator externally, or may generate and apply a therapeutic electrical signal based on internal calculations and programming.
  • the controller 410 is capable of affecting substantially all functions of the IMD 400.
  • the controller 410 may comprise various components, such as a processor 415, a memory 417, etc.
  • the processor 415 may comprise one or more microcontrollers, microprocessors, etc., that are capable of executing a variety of software components.
  • the memory 417 may comprise various memory portions, where a number of types of data (e.g., internal data, external data instructions, software codes, status data, diagnostic data, etc.) may be stored.
  • the memory 417 may store various tables or other database content that could be used by the IMD 400 to implement the override of normal operations.
  • the memory 417 may comprise random access memory (RAM) dynamic random access memory (DRAM), electrically erasable programmable read-only memory (EEPROM), flash memory, etc.
  • RAM random access memory
  • DRAM dynamic random access memory
  • EEPROM electrically erasable programmable read-only memory
  • flash memory etc.
  • the EMD 400 may also comprise a signal generation unit or pulse generator 420.
  • the signal generation unit 420 is capable of generating and delivering a variety of electrical neurostimulation signals to one or more electrodes, e.g., via leads.
  • the signal generation unit 420 is capable of generating a therapy portion, a ramping-up portion, and a ramping-down portion of the therapeutic electrical signal.
  • a number of leads may be used to electrically couple the one or more electrodes to the IMD 400.
  • the electrodes may be directly coupled to the signal generation unit 420.
  • the therapeutic electrical signal may be delivered to the electrodes by the signal generation unit 420 based upon instructions from the controller 410.
  • the signal generation unit 420 may comprise various types of circuitry, such as pulse generators, impedance control circuitry to control the impedance "seen” by the leads, and other circuitry that receives instructions relating to the type of electrical signal therapy to be provided to the patient.
  • the signal generation unit 420 is capable of delivering a controlled current therapeutic electrical signal to the electrodes.
  • the IMD 400 may also comprise a power supply 430.
  • the power supply 430 may comprise a battery, voltage regulators, capacitors, etc., to provide power for the operation of the IMD 400, including delivering the therapeutic electrical signal.
  • the power supply 430 provides power for the operation of the IMD 400, including electronic operations and the electrical signal function.
  • the power supply is typically a battery.
  • the power supply 430 may comprise a litnium/thionyl chloride cell or a lithium/carbon monofluoride cell. Other battery types known in the art of implantable medical devices may also be used. Any suitable batteries may be used including without limitation, lithium ion, nickel cadmium alkaline, and the like.
  • the power supply comprises a battery located inside support member 401 and coupled to the pulse generator 420.
  • the power supply is rechargeable.
  • the power supply may be wirelessly rechargeable.
  • a wirelessly rechargeable power supply may include an external power supply on the outside of the patient's body, inductively coupled to an implanted rectifier and/or capacitor attached to the support member 401. Such a power supply may be charged from outside the patient's body without requiring removal of the medical device.
  • the power supply 430 may comprise a power converter to convert energy from the patient's body into electrical power for the IMD 400.
  • the converter may use a temperature difference within the patient's body or between the patient's body and the environment to generate electrical power, or may convert body movement (e.g., gastric motility movement, arm movement, or leg movement) into electrical energy to provide power to the IMD 400.
  • body movement e.g., gastric motility movement, arm movement, or leg movement
  • an external power supply may be part of an external unit 120 as will be described below.
  • the IMD 400 also comprises a communication unit 460 capable of facilitating communications between the IMD 400 and various devices.
  • the communication unit 460 is capable of providing transmission and reception of electronic signals to and from an external unit 120.
  • communication unit 460 may be a wireless device capable of transmitting and receiving signals to and from IMD 400 without the use of wires.
  • the controller 410 and signal generator 420 may be part of an external unit or programming system 120, described in more detail below.
  • the external unit 120 may be a device that is capable of programming various modules and electrical signal parameters of the IMD 400.
  • the external unit 120 comprises a computer system that is capable of executing a data-acquisition program.
  • the external unit 120 may be controlled by a healthcare provider, such as a physician, at a base station in, for example, a doctor's office.
  • the external unit 120 may be a computer, preferably a handheld computer or PDA, but may alternatively comprise any other device that is capable of electronic communications and programming.
  • the external unit 120 may download various parameters and program software into the IMD 400 for programming the operation of the implantable device.
  • the external unit 120 may also receive and upload various status conditions and other data from the IMD 400.
  • the communication unit 460 may be hardware, software, firmware, and/or any combination thereof. Communications between the external unit 120 and the communication unit 460 may occur via a wireless or other type of communication, illustrated generally by line 475 in Figure 4.
  • the IMD 400 is capable of delivering a therapeutic electrical signal that can be intermittent, periodic, random, sequential, coded, and/or patterned.
  • the electrical signals may comprise an electrical signal frequency of approximately 0.1 to 1000 Hz.
  • the electrical signals may comprise a pulse width of in the range of approximately 1 - 2000 microseconds.
  • the electrical signals may comprise current amplitude in the range of approximately 0.1 mA to 10 mA.
  • the therapeutic electrical signal may be delivered through either bipolar electrodes (i.e., a cathode (-) electrode and an anode (+) electrode), or may be delivered through one or more unipolar electrodes.
  • the various blocks illustrated in Figure 4 may comprise a software unit, a firmware unit, a hardware unit, and/or any combination thereof.
  • the IMD 400 may also comprise a magnetic field detection unit 490.
  • the magnetic field detection unit 490 is capable of detecting magnetic and/or electromagnetic fields of a predetermined magnitude. Whether the magnetic field results from a magnet placed proximate to the IMD 400, or whether it results from a substantial magnetic field encompassing an area (such as an MRI machine), the magnetic field detection unit 490 is capable of informing the IMD of the existence of a magnetic field.
  • the magnetic field detection unit 490 may comprise various sensors, such as a Reed Switch circuitry, a Hall Effect sensor circuitry, and/or the like.
  • the magnetic field detection unit 490 may also comprise various registers and/or data transceiver circuits that are capable of sending signals that are indicative of various magnetic fields, the time period of such fields, etc. In this manner, the magnetic field detection unit 490 is capable of deciphering whether the detected magnetic field relates to an inhibitory input or an excitatory input from an external source.
  • the inhibitory input may refer to inhibition of, or deviation from, normal signal generation operation.
  • the excitatory input may refer to additional electrical signal therapy or deviation from normal electrical signal therapy.
  • the IMD 400 may also include an electrical signal override unit 480.
  • the electrical signal override unit 480 is capable of overriding the reaction by the IMD to the detection of a magnetic signal provided by the magnetic field detection unit 490.
  • the electrical signal override unit 480 may comprise various software, hardware, and/or firmware units that are capable of determining an amount of time period in which to override the detection of a magnetic field.
  • the signal override unit 480 may also contain safety features, such as returning to normal operation despite an override command after a predetermined period of time.
  • the electrical signal override unit 480 is capable of preventing false interruption of normal operation due to false magnetic input signals or unintended magnetic input signals.
  • the override unit 480 may receive an external indication via the communication unit 460 to engage in an override mode for a predetermined period of time.
  • components of IMD 400 are all coupled to support member 401 as described in detail above.
  • support member 401 and components of IMD 400 may be completely integrated into a compact and unitary device. That is, each component of IMD 400 may be integral to the support member 401.
  • the IMD 400 may be a complete standalone device without the need for any external devices to be carried around by a patient.
  • one of the many advantages of the IMD is that it may allow a patient to be completely ambulatory when the IMD is implanted, and providing maximum quality of life to the patient.
  • IMD may be temporary or permanent. That is, in some embodiments, IMD may be constructed to be inexpensive and easily disposable. For example, in particular embodiments, the IMD may be designed to be replaced once the power supply has been consumed. Such devices may be resident in the body of the patient for from several months up to several years, although shorter or longer residence times are possible. In other embodiments, IMD may be designed for permanent or long term operation such it will not need replacement for time periods of 10 years or more. Another advantage of the device is that it is easily removable.
  • FIGs 2 and 7 illustrate an external unit or programming system 120 comprising a programming device 124 coupled to a wand 128 for transmitting and receiving signals to and from the IMD 100.
  • the IMD 100 preferably comprises a signal or pulse generator 122, and a controller to control the generation and delivery of the electrical signal by the pulse generator 122.
  • the controller preferably is, or includes a central processing unit (CPU) such as a low-power, mixed-signal microcontroller.
  • the controller and pulse generator 122 may be part of an external programming system 120, described in more detail below.
  • the IMD 100 comprises a power supply which is coupled to the support member 101, and to the pulse generator 102.
  • the power supply is typically a battery, such as a lithium carbon monofluoride (LiCFx), lithium ion, nickel cadmium alkaline, and the like.
  • the power supply comprises a battery located inside support member 101 and coupled to the pulse generator 102.
  • the power supply is rechargeable.
  • the power supply may be wirelessly rechargeable.
  • a wirelessly rechargeable power supply may include an external power supply on the outside of the patient's body, inductively coupled to an implanted rectifier and/or capacitor attached to the support member 101.
  • FIGS. 2 and 7 further illustrate a programming system 120 comprising a programming device 124 coupled to a wand 128, for transmitting and receiving wireless signals (e.g., RF signals) to and from the IMD 100.
  • the programming device 124 may comprise a personal computer, personal digital assistant (PDA) device, or other suitable computing device consistent with the description contained herein.
  • PDA personal digital assistant
  • the IMD 100 includes a transceiver (such as a coil) that permits signals to be communicated wirelessly and non- invasively between the programming device 124 (via the external wand 128) and the implanted IMD 100.
  • Wand 128 facilitates wireless communication and may be placed on the skin of the patient's body overlying the implant site of the IMD 100.
  • the programming system 120 may also monitor the performance of the IMD 100 and download new programming parameters to define the therapeutic electrical signal (e.g., on-time, off -time, pulse width, current amplitude, frequency) into the IMD 100 to alter its operation as desired.
  • portions of the programming system may be integrated into the IMD 100, itself, or may be external to the IMD 100.
  • FIG. 7 shows a block diagram of one embodiment of the programming system 120.
  • the programming system 120 is external to the patient's body, and includes the programming device 124 and the wand 128.
  • Programming system 120 generally assists, controls, and/or programs the IMD 100 and may also receive data from the IMD referring to status and operational conditions stored in or generated by the IMD, such as battery and lead diagnostic information, remaining battery life calculations, current programming parameters, patient identification information, programming history information, etc.
  • the IMD 100 generates a therapeutic pulsed electrical signal for application to the vagus nerve 133 in a patient under the control of programming system 120.
  • Programming device 124 preferably includes a central processing unit (CPU) 236 such as a low-power, mixed-signal microcontroller.
  • CPU central processing unit
  • any suitable processor can be used to implement the functionality performed by the programming device 124 as explained herein.
  • some features of the programming system 120 may also be provided in whole, or in part, by the IMD 100, and vice versa. Thus, while certain features of the present invention may be described as part of the IMD 100, it is not intended thereby to preclude embodiments in which the features are provided by the programming system 120. Likewise, describing certain features herein as part of the programming system 120 does not preclude embodiments in which the features are included as part of the IMD 100.
  • the CPU 236 of programming device 124 is preferably coupled to a memory 250.
  • the memory 250 may comprise volatile (e.g.., random access memory) and/or non- volatile memory (e.g., read only memory (ROM), electrically-erasable programmable ROM (EEPROM), Rash memory, etc.).
  • Memory 250 may comprise any suitable storage medium. Examples of suitable storage media include without limitation, USB flash drives, Compact Rash cards, memory sticks, Smart Media cards, Secure Digital (SD) cards, xD cards, CD-ROM, DVD-ROM, tape drives, Zip disks, floppy disk, RAM, hard drives, etc.
  • the memory 250 may be used to store code (e.g., diagnostic software) that is executed by the CPU 236.
  • the executable code may be executed directly from the non- volatile memory or copied to a volatile memory for execution therefrom.
  • programming device 124 of programming system 120 may have a display or output 232 such that a user may monitor the functions or properties of the IMD 100.
  • programming system 120 may have a graphical user interface.
  • a user may input parameter settings using an input device 238 through the graphical user interface on the display 232, or other input means.
  • Memory 250 may store data received from the IMD 100 or may be used to store software 380 (e.g., diagnostic software, therapy programs, code, etc.) that is executed by the CPU 236.
  • the executable code may be executed directly from the non- volatile memory or copied to the volatile memory for execution therefrom.
  • the programming system 120 may be used by a physician as part of an office computer system, in which the IMD 100 is queried regularly during office visits by the patient.
  • programming system 120 may be ambulatory, and wand 128 may be continuously in contact with the patient's skin near implant site (i.e., the abdominal region) to provide continuous control of IMD 100 in conjunction with a portable handheld device 124 that may comprise, e.g., a PDA.
  • Wand 128 is coupled to the programming device 124 which may be conveniently worn by the patient on a belt, pocket, and the like.
  • programming device 124 and wand 128 are integrated into a single device which is kept in continuous proximity to the IMD 100 so as to maintain wireless communication with the IMD 100 through the skin.
  • an IMD 100 is implanted in the esophagus 131 of a patient. See Figures 8A- D.
  • the IMD 100 is implanted in the lower or abdominal portion of the esophagus 131 at or below the patient's diaphragm, e.g., where the anterior and posterior vagus nerves are attached to the exterior wall of the esophagus 131 near the esophagogastric junction.
  • the IMD 100 is delivered to the implantation site in the esophagus 131 orally i.e.
  • IMD 100 may be implanted via a catheter delivery system. Specifically, IMD 100 may be mounted at the end of a catheter 210, e.g., at a balloon portion 211 of a balloon catheter in its contracted position. The catheter 210 and IMD 100 may then be inserted into the patient's mouth and throat (Le. orally), and advanced into the esophagus as shown in Figure 8 A.
  • the catheter 210 is inserted until the distal tip is near the esophagogastric junction (i.e., at the intersection of the esophagus and the stomach) as this portion of the esophagus 131 is where the vagus nerve 133 reforms from the esophageal plexus to form the anterior and posterior vagal trunks. See Figure 8B.
  • the IMD 100 is deployed (for example, to an expanded position) and anchored to the inner wall of the esophagus.
  • the balloon portion may be inflated to expand the support member 101.
  • a balloon catheter may be used, for example, in conjunction with a support member comprising a stent or stent-like retainment element.
  • the support member 101 may comprise a wire or band of a shape-memory metal such as Nitinol or a resilient polymer to provide strength and additional support to the support member 101.
  • the support member 101 (with the retainment element) may be wrapped around, folded, compressed or otherwise reduced to a contracted position and retained in position on the catheter by sutures, releasable wires, or other constraining means known in the art, where a constraint is needed.
  • the IMD 100 deployed into place against the inner wall of the esophagus, Figure 8D by, for example, removing a the constraining means or expanding a balloon catheter.
  • the IMD 100 may then be anchored in place using anchors known in the art, e.g., sutures, barbs, staples, adhesives, pins, etc.
  • the anchors are the electrodes, which comprise barbs to engage and penetrate into the wall of the esophagus.
  • anchors are not used, and the device may be retained in place solely by a retainment element, such as a C-shaped spring embedded in the support member 101.
  • IMD 100 is implanted such that electrodes 103 are in contact with the inner wall surface of the esophagus 131.
  • the IMD 100 provides electrical signal therapy (e.g., vagus nerve stimulation) to a vagus nerve by applying a therapeutic electrical signal through one or more electrodes 103 to the inner surface of the esophagus wall, through the wall of the esophagus, and to the vagus nerve 133 on the outer surface of the esophagus 131.
  • electrical signal therapy e.g., vagus nerve stimulation
  • at least one electrode penetrates into the wall of the esophagus, and the electrical signal is applied to the wall of the esophagus, penetrates the outer wall, and generates action potentials in the vagus nerve.
  • the electrical signal may be defined an a variety of ways known in the art using a number of different parameters of the signal such as without limitation, pulse width, current amplitude, frequency, on-off time, duty cycle, number of pulses per burst, interburst period, interpulse interval, burst duration, or combinations thereof. In general, these parameters may be adjusted through the programming system 120.
  • Vagus nerve stimulation may involve non-feedback stimulation characterized by a number of parameters. Specifically, vagus nerve stimulation may involve a series of electrical pulses in bursts defined by an "on-time” and an "off-time.” During the on-time, electrical pulses of a defined electrical current (e.g., 0.5 - 10.0 milliamps) and pulse width (e.g., 0.25 - 1.5 milliseconds) are delivered at a defined frequency (e.g., 20 - 30 Hz) for the on-time duration, usually a specific number of seconds, e.g., 7 - 120 seconds.
  • a defined electrical current e.g., 0.5 - 10.0 milliamps
  • pulse width e.g., 0.25 - 1.5 milliseconds
  • vagus nerve stimulation may comprise a feedback stimulation scheme.
  • the on-time and off -time may be programmed to define an intermittent pattern in which a repeating series of electrical pulse bursts are generated and applied to the vagus nerve.
  • Each sequence of pulses during an on-time may be referred to as a "pulse burst.”
  • the burst is followed by the off-time period in which no signals are applied to the nerve.
  • the off-time is provided to allow the nerve to recover from the stimulation of the pulse burst, and to conserve power. If the off-time is set at zero, the electrical signal in conventional VNS may provide continuous stimulation to the vagus nerve.
  • the ratio of "off-time" to "on-time” may range from about 0.5 to about 10.
  • the other parameters defining the electrical signal in conventional VNS may be programmed over a range of values.
  • the pulse width for the pulses in a pulse burst of conventional VNS may be set to a value not greater than about 1 msec, such as about 250-500 ⁇ sec, and the number of pulses in a pulse burst is typically set by programming a frequency in a range of about 20-150 Hz (i.e., 20 pulses per second to 150 pulses per second).
  • a non-uniform frequency may also be used. Frequency may be altered during a pulse burst by either a frequency sweep from a low frequency to a high frequency, or vice versa.
  • the timing between adjacent individual signals within a burst may be randomly changed such that two adjacent signals may be generated at any frequency within a range of frequencies.
  • the electrical signal may be varied in a number of ways known in the art using a number of different parameters of the signal such as without limitation, pulse width, current amplitude, frequency, on-off time, duty cycle, number of pulses per burst, interburst period, interpulse interval, burst duration, or combinations thereof. In general, these parameters may be adjusted through the programming system 120.
  • Embodiments of the IMD may be used to treat a wide variety of medical conditions without exposing the patient to surgical complications, including without limitation epilepsy, neuropsychiatric disorders (including but not limited to depression), eating disorders/obesity, traumatic brain injury/coma, addiction disorders, dementia, sleep disorders, pain, migraine, endocrine/pancreatic disorders (including but not limited to diabetes), motility disorders, hypertension, congestive heart failure/cardiac capillary growth, hearing disorders, angina, syncope, vocal cord disorders, thyroid disorders, pulmonary disorders, and reproductive endocrine disorders (including fertility) in a patient.
  • epilepsy neuropsychiatric disorders (including but not limited to depression), eating disorders/obesity, traumatic brain injury/coma, addiction disorders, dementia, sleep disorders, pain, migraine, endocrine/pancreatic disorders (including but not limited to diabetes), motility disorders, hypertension, congestive heart failure/cardiac capillary growth, hearing disorders, angina, syncope, vocal cord disorders, thyroid disorders
  • the IMD may be easily deployed and may also avoid undesired side effects, in particular voice alteration, by providing a therapeutic electrical signal to the vagus nerve in a location remote from the larynx compared to conventional vagus nerve stimulation systems implanted in the neck area.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Electrotherapy Devices (AREA)

Abstract

L'invention concerne des dispositifs et des procédés non chirurgicaux qui fournissent une thérapie du nerf vague par voie trans-œsophagienne en vue traiter une variété d'états médicaux. Dans un mode de réalisation, un dispositif médical implantable comprend un élément support possédant une surface externe. L'élément support est adapté pour s'engager dans la paroi interne d'un œsophage. Le dispositif médical implantable comprend également au moins une électrode placée sur la surface externe de l'élément support. Ladite au moins une électrode est capable d'appliquer un signal électrique trans-œsophagien au nerf vague à travers la paroi de l'œsophage à partir de la lumière interne de celui-ci. Le dispositif médical implantable comprend en outre un générateur de signaux couplé à l'élément support et à ladite au moins une électrode. Le générateur de signaux amène ladite au moins une électrode à appliquer un signal électrique au nerf vague pour traiter un état médical.
EP08727307A 2007-04-26 2008-04-07 Dispositif non chirurgical et procédés de stimulation du nerf vague trans- sophagien Withdrawn EP2136873A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/796,158 US7869884B2 (en) 2007-04-26 2007-04-26 Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US11/796,058 US7904175B2 (en) 2007-04-26 2007-04-26 Trans-esophageal vagus nerve stimulation
PCT/US2008/004469 WO2008133797A1 (fr) 2007-04-26 2008-04-07 Dispositif non chirurgical et procédés de stimulation du nerf vague trans-œsophagien

Publications (1)

Publication Number Publication Date
EP2136873A1 true EP2136873A1 (fr) 2009-12-30

Family

ID=41354053

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08727307A Withdrawn EP2136873A1 (fr) 2007-04-26 2008-04-07 Dispositif non chirurgical et procédés de stimulation du nerf vague trans- sophagien

Country Status (3)

Country Link
EP (1) EP2136873A1 (fr)
CA (1) CA2685028A1 (fr)
WO (1) WO2008133797A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8457757B2 (en) 2007-11-26 2013-06-04 Micro Transponder, Inc. Implantable transponder systems and methods
US9089707B2 (en) 2008-07-02 2015-07-28 The Board Of Regents, The University Of Texas System Systems, methods and devices for paired plasticity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7840278B1 (en) * 1999-06-25 2010-11-23 Puskas John D Devices and methods for vagus nerve stimulation
US7844338B2 (en) * 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20050209653A1 (en) * 2004-03-16 2005-09-22 Medtronic, Inc. Intra-luminal device for gastrointestinal electrical stimulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008133797A1 *

Also Published As

Publication number Publication date
WO2008133797A1 (fr) 2008-11-06
CA2685028A1 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
US7904175B2 (en) Trans-esophageal vagus nerve stimulation
US7869884B2 (en) Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7962214B2 (en) Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US8560076B2 (en) Devices and methods for electrode implantation
US7502650B2 (en) Baroreceptor activation for epilepsy control
US20240157126A1 (en) Modular Stimulation System for the Treatment of Gastrointestinal Disorders
US9827425B2 (en) Methods and systems of electrode polarity switching in electrical stimulation therapy
ES2454870T3 (es) Neuroestimulación con una duración de señal determinada por un ciclo cardiaco
US20060173493A1 (en) Multi-phasic signal for stimulation by an implantable device
US20080195188A1 (en) Implantable medical device with fixation mechanism
EP1885438A1 (fr) Systemes de stimulation electrique des nerfs dans des regions tissulaires adipeuses
US11839407B2 (en) Treatment of obstructive sleep apnea (OSA)
EP2136873A1 (fr) Dispositif non chirurgical et procédés de stimulation du nerf vague trans- sophagien
US11666751B2 (en) Combination obstructive sleep apnea trialing lead and chronic lead
JP2012120665A (ja) 電気刺激装置および電極リード
WO2024091837A1 (fr) Élément de fixation d'implant pour l'apnée obstructive du sommeil
WO2024025686A1 (fr) Aiguille pour implantation de fil pour apnée du sommeil obstructive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100610

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111101